Intravitreal injection of bevacizumab to treat neovascular glaucoma.
Kubota
Toshiaki
T
Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. tkubota@med.uoeh-u.ac.jp.
Aoki
Rumi
R
Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Harada
Yukinori
Y
Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tou
Norihiko
N
Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tawara
Akihiko
A
Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab